Summary:
This week on The Genetics Podcast, Patrick is joined by Frank Gleeson, co-founder and CEO of Satellos. They discuss Satellos’ novel approach to treating Duchenne Muscular Dystrophy by targeting muscle stem cell regeneration, how this fills a critical therapeutic gap, and the promising results of their early clinical trials. They also touch on what it takes to advance drug development and secure funding in today’s biotech landscape.
Show Notes:
0:00 Intro to The Genetics Podcast
01:00 Welcome to Frank and the origin story for Satellos and its focus on muscle stem cell regeneration to treat Duchenne Muscular Dystrophy (DMD)
14:03 Counteracting degeneration in DMD and associated mechanisms
16:08 Current therapeutic focuses in DMD, including gene therapy and exon skipping to increase expression of dystrophin
24:28 Satellos’ drug development strategy, safety-first design, and early clinical findings in adults with DMD
35:54 The study design and number of patients for Satellos’ phase 2 trial
40:12 Frank’s recommendations for how biotechs can raise funding in today’s climate
44:38 Advantages of Frank’s career path across business and venture capital to biotech
46:52 Closing remarks
Find out more
Satellos (https://satellos.com/)
Please consider rating and reviewing us on your chosen podcast listening platform!
https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link